MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Merck KGaA (MKGAF)
Organization & Developments: Merck KgaA
Parents
Merck KGaA (MKGAF)
Children
2012: Merck KGaA Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc. (THLD) (2012)
2021: Merck KGaA lands rights to 3rd F-star oncology bispecific antibody
2022: Has attracted the interest of Big Pharma, with the latest investors including the venture capital arms of Merck KGaA, Johnson & Johnson and Pfizer, along with Oxford Science Enterprises and British Patient Capital, a wholly owned commercial subsidiary of the U.K. government’s economic development bank.
2022: Merck KGaA turns to deals, 'leaner' organization to expedite R&D. Will layoffs follow?
2023: Merck KGaA: Company With A Potential Upside (OTCMKTS:MKGAF)
2024: Merck KGaA: A Continued Long-Term Upside Despite Some Lag
2024: Merck KGaA: The Drop Makes The Upside All The Sweeter
M Ventures
The group includes around 250 companies
the main company is Merck KGaA in Germany
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 57,000 employees and present in 66 countries.
Jumps
Finance & Acquisitions: Merck KgaA
Key People: Merck KgaA